Quantbot Technologies LP Purchases New Position in Baxter International Inc. $BAX

Quantbot Technologies LP acquired a new position in Baxter International Inc. (NYSE:BAX) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 100,127 shares of the medical instruments supplier’s stock, valued at approximately $2,135,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of BAX. Allworth Financial LP purchased a new stake in shares of Baxter International during the second quarter worth $123,000. E Fund Management Co. Ltd. bought a new stake in shares of Baxter International during the 2nd quarter valued at $355,000. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Baxter International during the 2nd quarter valued at $51,958,000. Tocqueville Asset Management L.P. purchased a new stake in Baxter International during the 2nd quarter worth about $30,604,000. Finally, NewEdge Wealth LLC bought a new position in Baxter International in the 2nd quarter worth about $922,000. Institutional investors own 90.19% of the company’s stock.

Baxter International Trading Up 0.6%

Shares of BAX opened at $26.50 on Tuesday. The firm’s 50 day simple moving average is $23.74 and its 200 day simple moving average is $20.41. The company has a market capitalization of $13.70 billion, a P/E ratio of -12.80, a P/E/G ratio of 3.99 and a beta of 0.60. The company has a debt-to-equity ratio of 1.39, a current ratio of 1.95 and a quick ratio of 1.32. Baxter International Inc. has a 1-year low of $15.73 and a 1-year high of $30.00.

Baxter International (NYSE:BAX) last released its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. The business had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $2.80 billion. Baxter International had a negative net margin of 9.27% and a positive return on equity of 16.57%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.59 EPS. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. Sell-side analysts forecast that Baxter International Inc. will post 2.04 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Friday, August 28th will be given a $0.01 dividend. The ex-dividend date is Friday, August 28th. This represents a $0.04 annualized dividend and a yield of 0.2%. Baxter International’s payout ratio is -1.93%.

Analyst Ratings Changes

BAX has been the topic of a number of recent analyst reports. TD Cowen increased their price target on shares of Baxter International from $20.00 to $24.00 and gave the stock a “hold” rating in a report on Monday, July 27th. Citigroup upgraded shares of Baxter International from a “sell” rating to a “neutral” rating and increased their target price for the stock from $17.00 to $28.00 in a research note on Friday, July 31st. The Goldman Sachs Group raised their price target on shares of Baxter International from $19.00 to $21.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Stifel Nicolaus upped their price target on shares of Baxter International from $19.00 to $24.00 and gave the stock a “hold” rating in a report on Tuesday, July 28th. Finally, Zacks Research upgraded Baxter International from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $22.45.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.